Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. A0026
2. Bay 56-6854
3. Bay 566854
4. Bay-56-6854
5. Bay-566854
6. Bay56-6854
7. Bay566854
8. Faropenem Medoxomil
9. Sun 208
10. Sun A0026
11. Sun-208
12. Sun-a0026
13. Sun208
1. 141702-36-5
2. Faropenem Medoxomil
3. Faropenem Medoxil
4. Sun-a0026
5. Fropenem Daloxate
6. Faropenem Medoxomil [usan]
7. Bay-56-6854
8. A-0026
9. 5ok523o4fu
10. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (5r,6s)-6-[(1r)-1-hydroxyethyl]-7-oxo-3-[(2r)-oxolan-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
11. A0026
12. Sun-208
13. Faropenem Medoxomil (usan)
14. Orapem
15. 4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic Acid, 6-[(1r)-1-hydroxyethyl]-7-oxo-3-[(2r)-tetrahydro-2-furanyl]-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl Ester, (5r,6s)-
16. Unii-5ok523o4fu
17. Faropenem-medoxomil
18. Bay 566854
19. Bay 56-6854
20. A 0026
21. Schembl2334640
22. Sun208
23. Faropenem Daloxate [mi]
24. Chembl1257070
25. Sun A0026
26. Sun 208
27. Chebi:134710
28. Zinc3806644
29. Bay566854
30. Bay-566854
31. Bay56-6854
32. Cs-0390
33. Db05659
34. Hy-10004
35. D08919
36. 702f365
37. A911194
38. Q27095691
39. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (5r,6s)-6-((1r)-1-hydroxyethyl)-7-oxo-3-((2r)-tetrahydrofuran-2-yl)-4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylate
40. (5-methyl-2-oxo-1,3-dioxoren-4-yl)methyl(5r,6s)-6-((r)-1-hydroxyethyl)-7-oxo-3-((r)-2-tetrahydrofuryl)-4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylate
41. (5r,6s)-6-[(1r)-1-hydroxyethyl]-7-oxo-3-[(2r)-oxolane-2-yl]-4-thia-1-azabicyclo[3.2.0]hepta-2-ene-2-carboxylic Acid 5-methyl-2-oxo-1,3-dioxole-4-ylmethyl Ester
42. 4-thia-1-azabicyclo(.32.0)hept-2-ene-2-carboxylic Acid, 6-((1r)-1-hydroxyethyl)-7-oxo-3-((2r)-tetrahydro-2-furanyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl Ester, (5r,6s)-
43. 4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic Acid, 6-((1r)-1-hydroxyethyl)-7-oxo-3-((2r)-tetrahydro-2-furanyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl Ester, (5r,6s)
44. 4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic Acid, 6-(1-hydroxyethyl)-7-oxo-3-(tetrahydro-2-furanyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl Ester, (5r-(3(r*),5alpha,6alpha(r*)))-
45. 4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic Acid, 6-[(1r)-1-hydroxyethyl]-7-oxo-3-[(2r)-tetrahydro-2-furanyl]-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl Ester
| Molecular Weight | 397.4 g/mol |
|---|---|
| Molecular Formula | C17H19NO8S |
| XLogP3 | 0.9 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 6 |
| Exact Mass | 397.08313774 g/mol |
| Monoisotopic Mass | 397.08313774 g/mol |
| Topological Polar Surface Area | 137 Ų |
| Heavy Atom Count | 27 |
| Formal Charge | 0 |
| Complexity | 775 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in bacterial infection, bronchitis, otitis media, and pediatric indications.
Faropenem has demonstrated excellent in vitro activity against common respiratory pathogens, many aerobic gram-positive organisms, and anaerobes. Activity against gram-negative organisms is more reserved. In vivo data suggest that faropenem is efficacious in treating community-acquired infections including uncomplicated skin and skin structure infections; however, more data may help to characterize faropenem's place in antimicrobial therapy.
Like other beta-lactam antibiotics, faropenem acts by inhibiting the synthesis of bacterial cell walls. It inhibits cross-linkage between the linear peptidoglycan polymer chains that make up a major component of the cell wall of Gram-positive bacteria. It does this by binding to and competitively inhibiting the transpeptidase enzyme used by bacteria to cross-link the peptide (D-alanyl-alanine) used in peptidogylcan synthesis.
Digital Content 
NEWS #PharmaBuzz
Market Place
ABOUT THIS PAGE
A Faropenem Medoxomil manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Faropenem Medoxomil, including repackagers and relabelers. The FDA regulates Faropenem Medoxomil manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Faropenem Medoxomil API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Faropenem Medoxomil supplier is an individual or a company that provides Faropenem Medoxomil active pharmaceutical ingredient (API) or Faropenem Medoxomil finished formulations upon request. The Faropenem Medoxomil suppliers may include Faropenem Medoxomil API manufacturers, exporters, distributors and traders.
click here to find a list of Faropenem Medoxomil suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Faropenem Medoxomil DMF (Drug Master File) is a document detailing the whole manufacturing process of Faropenem Medoxomil active pharmaceutical ingredient (API) in detail. Different forms of Faropenem Medoxomil DMFs exist exist since differing nations have different regulations, such as Faropenem Medoxomil USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Faropenem Medoxomil DMF submitted to regulatory agencies in the US is known as a USDMF. Faropenem Medoxomil USDMF includes data on Faropenem Medoxomil's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Faropenem Medoxomil USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Faropenem Medoxomil suppliers with USDMF on PharmaCompass.
Faropenem Medoxomil Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Faropenem Medoxomil GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Faropenem Medoxomil GMP manufacturer or Faropenem Medoxomil GMP API supplier for your needs.
A Faropenem Medoxomil CoA (Certificate of Analysis) is a formal document that attests to Faropenem Medoxomil's compliance with Faropenem Medoxomil specifications and serves as a tool for batch-level quality control.
Faropenem Medoxomil CoA mostly includes findings from lab analyses of a specific batch. For each Faropenem Medoxomil CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Faropenem Medoxomil may be tested according to a variety of international standards, such as European Pharmacopoeia (Faropenem Medoxomil EP), Faropenem Medoxomil JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Faropenem Medoxomil USP).
LOOKING FOR A SUPPLIER?
